erlotinib hydrochloride has been researched along with Neoplasms, Squamous Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JC; Cheng, HH; Chiang, CS; Chien, CC; Hsieh, JM; Huang, IH; Ko, JC; Lin, YW; Liu, LL; Tsao, YC; Tseng, PY; Wei, CL | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Duyster, J; Kancha, RK; Kunst, PW; Reinten, RJ; van der Ven, WH; van Noesel, CJ; van Noesel, J; van Os, TA; Weegenaar, J | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
1 review(s) available for erlotinib hydrochloride and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
3 other study(ies) available for erlotinib hydrochloride and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Down-Regulation; Erlotinib Hydrochloride; Fluorouracil; Humans; Lung Neoplasms; Neoplasms, Squamous Cell; p38 Mitogen-Activated Protein Kinases; Rad52 DNA Repair and Recombination Protein | 2021 |
Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
Topics: Adult; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Family Health; Fatal Outcome; Female; Germ-Line Mutation; Humans; In Situ Hybridization; Lung; Lung Neoplasms; Middle Aged; Mutation, Missense; Neoplasms, Squamous Cell; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |